Investigating L-Arginine's effect on kidney injury after heart surgery
Association Between Early Postoperative L-Arginine Administration and Acute Kidney Injury Following Cardiac Surgery
Xijing Hospital · NCT06248359
This study is testing if giving L-Arginine to adults after heart surgery can help lower the chances of kidney injury.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Xijing Hospital (other) |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT06248359 on ClinicalTrials.gov |
What this trial studies
This study examines the relationship between the early administration of L-Arginine following cardiopulmonary bypass (CPB) during cardiac surgery and the occurrence of acute kidney injury (AKI) in adult patients. It aims to determine if L-Arginine can effectively reduce the incidence of post-operative AKI. The study is observational and focuses on patients who have undergone CPB-assisted cardiac surgery and are admitted to the ICU for recovery.
Who should consider this trial
Good fit: Ideal candidates are adult patients over 18 years old who have undergone CPB-assisted cardiac surgery and are admitted to the ICU.
Not a fit: Patients with congenital heart disease, those who underwent deep hypothermic circulatory arrest, or those with a glomerular filtration rate below 30 mL/min/1.73 m² may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to improved kidney health and recovery outcomes for patients undergoing cardiac surgery.
How similar studies have performed: There is limited information on similar studies, making this approach relatively novel in the context of post-operative AKI management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients (over 18 years) * underwent CPB assisted cardiac surgery * admitted to ICU Exclusion Criteria: * congenital heart disease * underwent deep hypothermic circulatory arrest (DHCA) * with glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²
Where this trial is running
Xi'an, Shaanxi
- Xijing Hospital — Xi'an, Shaanxi, China (RECRUITING)
Study contacts
- Principal investigator: Chong Lei — Xijing Hospital
- Study coordinator: Ziyu Zheng
- Email: zhengziyu@126.com
- Phone: +86-13228082320
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Kidney Injury